Jim Simons Acurx Pharmaceuticals, Inc. Call Options Transaction History
Renaissance Technologies LLC
- $70.6 Billion
- Q2 2025
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding ACXP
# of Institutions
36Shares Held
2.69MCall Options Held
62.9KPut Options Held
56.9K-
Armistice Capital, LLC New York, NY1.08MShares$4.78 Million0.01% of portfolio
-
Prospect Financial Services LLC Melville, NY367KShares$1.62 Million0.08% of portfolio
-
Geode Capital Management, LLC Boston, MA146KShares$648,5690.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA146KShares$644,7280.0% of portfolio
-
Morgan Stanley New York, NY106KShares$470,4700.0% of portfolio
About Acurx Pharmaceuticals, Inc.
- Ticker ACXP
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 11,556,600
- Market Cap $51.2M
- Description
- Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase II clinical trial to treat patients with clostridium difficile infections. The com...